Author: Kari Lehtipuu

Artificial intelligence (AI) tools have generated significant enthusiasm in recent times, particularly within healthcare. Generative AI tools like OpenAI’s

Health data can be extremely useful for research, innovation, and development, but can only be freely utilized if identifying

Following the passage of the European General Data Protection Regulation (GDPR) in 2018, there has been much confusion between

AI-based next-generation anonymization technology developed in Finland enables versatile and high-quality research utilization of health data. Bayer, a pharmaceutical

Drug development is a laborious, time-consuming process. On average, developing a new drug takes 10 years – about seven

The BioInnovation Institute (BII), an international commercial non-profit foundation incubating and accelerating world-class life science research, today announces its

Welcome to meet us at HIMSS (booth 814) to hear how next generation anonymization technology brings the quality of

“…It is important to get moving on your data-driven journey…” Data is becoming more important for pharmaceutical companies every

Subscribe to our newsletter